|
1
|
August 2003
|
GTG, FISH (WCP probes)
|
WBC 327×109/l with 73% neutrophils, 23% lymphocytes, 3% monocytes and 1% eosinophiles. Hgb 11.9 g/dl and Plts 540×109/l.
|
-
|
46,XX,t(9;22)[20]
|
|
2
|
November 2005
|
GTG, FISH (BCR/ABL and WCP probes)
|
WBC 7.9×109/l with 66% neutrophils, 31% lymphocytes, 2% monocytes and 1% eosinophiles. Hgb 11.2 g/dl and Plts 371×109/l.
|
Imatinib mesylate at 200 mg/day for overall 12 months
|
46,XX,t(9;22)[20]
|
|
3
|
November 2006
|
GTG, FISH (BCR/ABL probe)
|
WBC 6.8×109/l with 64% neutrophils, 33% lymphocytes, 2% monocytes and 1% eosinophiles. Hgb 12.8 g/dl and Plts 305×109/l.
|
Imatinib at 400 mg/day for overall 12 months
|
46,XX,t(9;22)[20]
|
|
4
|
November 2008; patients interrupted treatment for ~12 months; Nitolib was initiated November 2009
|
GTG, FISH, RT-PCR, RFLP
|
WBC 15.5×109/l with 54% neutrophils, 43% lymphocytes, 3% monocytes and 1% eosinophiles. Hgb 8.8 g/dl and Plts 215×109/l.
|
Imatinib at 400 mg/day for overall 12 months in the total.
|
45,XX,t(9;22),+dic(17;18),-17,-18[20]
|
| | | | | |
b2a2 transcript
|
| | | | | |
T315I mutation
|
|
5
|
March 2010
|
GTG, FISH, RT-PCR, RFLP
|
WBC 2.2×109/l with 25% neutrophils, 73% lymphocytes, 1% monocytes and 1% eosinophiles. Hgb 9.5 g/dl and Plts 111x109/l.
|
nilotinib at 800 mg/day for overall 5 months.
|
45,XX,t(9;22),+dic(17;18),-17,-18 [16]/46,XX,t(9;22)[4]
|
| | | | | |
co-expression of b2a2 and b3a2 transcript.
|
| | | | | |
T315I mutation
|
|
6
|
November 2010
|
The patient passed away under the treatment due to unknown reasons
|
